Giant Prolactinoma Presenting with Neck Pain and Structural Compromise of the Occipital Condyles

Abstract

Prolactinomas are the most common form of endocrinologically active pituitary adenoma; they account for ∼ 45% of pituitary adenomas encountered in clinical practice. Giant adenomas are those > 4 cm in diameter. Less than 0.5% of pituitary adenomas encountered in neurosurgical practice are giant prolactinomas. Patients with giant prolactinomas typically present with highly elevated prolactin levels, endocrinologic disturbances, and neurologic symptoms from mass-induced pressure. Described here is an unusual case of a giant prolactinoma presenting with neck pain and structural compromise of the occipital condyles. Transnasal biopsy of the nasopharyngeal portion of the mass obtained tissue consistent with an atypical prolactinoma with p53 reactivity and a high Ki-67 index of 5%. Despite the size and invasiveness of the tumor, the patient had resolution of his clinical symptoms, dramatic reduction of his hyperprolactinemia, and near-complete disappearance of his tumor following medical treatment.

Keywords

pituitary adenoma - giant prolactinoma - occipitocervical instability - occipital condyles - invasive adenoma

• References

• 1 Ezzat S, Asa SL, Couldwell WT , et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004; 101 (3) 613-619
• 2 Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary 2005; 8 (1) 3-6
• 3 Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 2000; 85 (9) 3053-3057
• 4 Shrivastava RK, Arginteanu MS, King WA, Post KD. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 2002; 97 (2) 299-306
• 5 Murphy FY, Vesely DL, Jordan RM, Flanigan S, Kohler PO. Giant invasive prolactinomas. Am J Med 1987; 83 (5) 995-1002
• 6 Zaben MJ, Harrisson SE, Mathad NV. Giant prolactinoma causing cranio-cervical junction instability: a case report. Br J Neurosurg 2011; 25 (6) 754-756
• 7 Laws Jr ER, Ivins JC. Atlanto-occipital instability as a result of pituitary adenoma: case report with successful management by cervico-occipital fusion. Johns Hopkins Med J 1979; 145 (3) 136-138
• 8 Chaudhary V, Bano S. Imaging of the pituitary: recent advances. Indian J Endocrinol Metab 2011; 15 (Suppl. 03) S216-S223
• 9 Yeom KW, Lober RM, Mobley BC , et al. Diffusion-weighted MRI: distinction of skull base chordoma from chondrosarcoma. AJNR Am J Neuroradiol 2013; 34 (5) 1056-1061 ; S1
• 10 Pisaneschi M, Kapoor G. Imaging the sella and parasellar region. Neuroimaging Clin N Am 2005; 15 (1) 203-219
• 11 Wong K, Raisanen J, Taylor SL, McDermott MW, Wilson CB, Gutin PH. Pituitary adenoma as an unsuspected clival tumor. Am J Surg Pathol 1995; 19 (8) 900-903
• 12 Ballaux D, Verhelst J, Pickut B, De Deyn PP, Mahler C. Ectopic macroprolactinoma mimicking a chordoma: a case report. Endocr Relat Cancer 1999; 6 (1) 117-122
• 13 Rocque BG, Herold KA, Salamat MS, Shenker Y, Kuo JS. Symptomatic hyperprolactinemia from an ectopic pituitary adenoma located in the clivus. Endocr Pract 2009; 15 (2) 143-148
• 14 Wan Y, Xie D, Yang S , et al. Acromegaly with an ectopic clival pituitary adenoma: case report and review of literature. Neurosurg Q 2015; 25 (1) 105-107
• 15 DeLellis R, Loyd R, Hetiz P, Eng C eds. World Health Organization Classification of Tumours: Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004
• 16 Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 2007; 156 (2) 203-216
• 17 Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws Jr ER. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 2011; 114 (2) 336-344
• 18 Thapar K, Kovacs K, Scheithauer BW , et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996; 38 (1) 99-106 ; discussion 106–107
• 19 Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws Jr ER. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 1996; 38 (4) 765-770 ; discussion 770–771
• 20 Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. J Neurosurg 2003; 98 (2) 359-365
• 21 Ma W, Ikeda H, Yoshimoto T. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas. Cancer 2002; 95 (2) 258-266
• 22 Oliveira MC, Marroni CP, Pizarro CB, Pereira-Lima JF, Barbosa-Coutinho LM, Ferreira NP. Expression of p53 protein in pituitary adenomas. Braz J Med Biol Res 2002; 35 (5) 561-565
• 23 Gejman R, Swearingen B, Hedley-Whyte ET. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 2008; 39 (5) 758-766
• 24 Trouillas J, Roy P, Sturm N , et al; members of HYPOPRONOS. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 2013; 126 (1) 123-135
• 25 Shimon I, Benbassat C, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 2007; 156 (2) 225-231
• 26 Corsello SM, Ubertini G, Altomare M , et al. Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf) 2003; 58 (5) 662-670
• 27 Acharya SV, Gopal RA, Menon PS, Bandgar TR, Shah NS. Giant prolactinoma and effectiveness of medical management. Endocr Pract 2010; 16 (1) 42-46
• 28 Cho EH, Lee SA, Chung JY , et al. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. J Korean Med Sci 2009; 24 (5) 874-878
• 29 Rahmanian M, Meybodi HA, Larijani B, Mohajeri-Tehrani MR. Giant prolactinoma: case report and review of literature. J Diabetes Metab Disord 2013; 12 (1) 3
• 30 Zhao B, Wei YK, Li GL , et al. Extended transsphenoidal approach for pituitary adenomas invading the anterior cranial base, cavernous sinus, and clivus: a single-center experience with 126 consecutive cases. J Neurosurg 2010; 112 (1) 108-117
• 31 Sinha S, Sharma BS. Giant pituitary adenomas—an enigma revisited. Microsurgical treatment strategies and outcome in a series of 250 patients. Br J Neurosurg 2010; 24 (1) 31-39
• 32 Garibi J, Pomposo I, Villar G, Gaztambide S. Giant pituitary adenomas: clinical characteristics and surgical results. Br J Neurosurg 2002; 16 (2) 133-139
• 33 Goel A, Nadkarni T, Muzumdar D, Desai K, Phalke U, Sharma P. Giant pituitary tumors: a study based on surgical treatment of 118 cases. Surg Neurol 2004; 61 (5) 436-445 ; discussion 445–446
• 34 Mortini P, Barzaghi R, Losa M, Boari N, Giovanelli M. Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients. Neurosurgery 2007; 60 (6) 993-1002 ; discussion 1003–1004
• 35 Leong KS, Foy PM, Swift AC, Atkin SL, Hadden DR, MacFarlane IA. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol (Oxf) 2000; 52 (1) 43-49
• 36 Suliman SG, Gurlek A, Byrne JV , et al. Nonsurgical cerebrospinal fluid rhinorrhea in invasive macroprolactinoma: incidence, radiological, and clinicopathological features. J Clin Endocrinol Metab 2007; 92 (10) 3829-3835
• 37 Machicado JD, Varghese JM, Orlander PR. Cabergoline-induced pneumocephalus in a medically treated macroprolactinoma. J Clin Endocrinol Metab 2012; 97 (10) 3412-3413
• 38 Knoepfelmacher M, Gomes MC, Melo ME, Mendonca BB. Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma. Pituitary 2004; 7 (2) 83-87
• 39 Jones SE, James RA, Hall K, Kendall-Taylor P. Optic chiasmal herniation—an under recognized complication of dopamine agonist therapy for macroprolactinoma. Clin Endocrinol (Oxf) 2000; 53 (4) 529-534
• 40 Lou XH, Wu ZB, Zhang YZ. Bromocriptine-induced brainstem angulation in a patient with invasive prolactinoma. J Clin Endocrinol Metab 2013; 98 (3) 867-868